SCHEMBL5539707

SCHEMBL5539707

[O]c1cccc2c1C(=O)CO2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.38
HSD17B10 Q99714 3/20 0.38
MAPT P10636 3/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
MAOB P27338 4/20 0.33
MAOA P21397 2/20 0.33
GAA P10253 1/20 0.33
PARP1 P09874 1/20 0.33
ALDH1A1 P00352 1/20 0.32
TYMS P04818 1/20 0.32
CYP1A2 P05177 1/20 0.32
HPGD P15428 1/20 0.32
CYP2C19 P33261 1/20 0.32
PKM P14618 1/20 0.32
TSHR P16473 1/20 0.32
NOTUM Q6P988 1/20 0.32
ATM Q13315 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
ABCG2 Q9UNQ0 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9780105 0.78 TSHR (0.40) KDM4EHSD17B10MAPTCASP1CASP7
SCHEMBL10158539 0.78 MAPT (0.42) KDM4EHSD17B10MAPTCASP1CASP7
SCHEMBL8790746 0.78 ADORA2A (0.38) KDM4EHSD17B10MAPTCASP1CASP7
SCHEMBL1265859 0.78 NOTUM (0.47) KDM4EHSD17B10MAPTCASP1CASP7
SCHEMBL1137861 0.78 MAPT (0.47) KDM4EHSD17B10MAPTCASP1CASP7
SCHEMBL17397682 0.78 KDM4E (0.37) KDM4EHSD17B10MAPTCASP1CASP7
SCHEMBL3411326 0.73 MAPT (0.42) KDM4EHSD17B10MAPTCASP1CASP7
SCHEMBL1922596 0.73 KDM4E (0.55) KDM4EHSD17B10MAPTCASP1CASP7
SCHEMBL4327142 0.73 THRB (0.42) KDM4EHSD17B10MAPTCASP1CASP7
SCHEMBL5537181 0.72 MMP12 (0.35) KDM4EHSD17B10MAPTCASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KDM4E 4854/4885HSD17B10 467/4885MAPT 4117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.